Filtered By:
Drug: Warfarin

This page shows you your search results in order of date. This is page number 14.

Order by Relevance | Date

Total 3661 results found since Jan 2013.

Temporal trends in anticoagulation management for US active duty personnel with atrial fibrillation
Conclusions This is the first report describing AC utilisation in US AD military members with AF. Young AD personnel with low stroke and bleeding risks do not commonly receive AC prescriptions. DOAC prescription rates are increasing and predominate over warfarin for AC indications.
Source: BMJ Open - November 29, 2022 Category: General Medicine Authors: Keithler, A. N., Wilson, A. S., Yuan, A., Sosa, J. M., Bush, K. N. V. Tags: Open access, Cardiovascular medicine Source Type: research

Prognostic impact of heart rate during atrial fibrillation on clinical outcomes in elderly non-valvular atrial fibrillation patients: ANAFIE Registry sub-cohort study
CONCLUSIONS: Elderly Japanese patients with non-paroxysmal NVAF and a heart rate ≥110 bpm have an increased risk of cardiac events. There was no interaction between heart rate category and the relative risk of adverse clinical events in patients taking DOACs compared with those taking warfarin.PMID:36427691 | DOI:10.1016/j.jjcc.2022.11.011
Source: Journal of Cardiology - November 25, 2022 Category: Cardiology Authors: Takanori Ikeda Takeshi Yamashita Masaharu Akao Hirotsugu Atarashi Yukihiro Koretsune Ken Okumura Wataru Shimizu Shinya Suzuki Hiroyuki Tsutsui Kazunori Toyoda Atsushi Hirayama Masahiro Yasaka Takenori Yamaguchi Satoshi Teramukai Tetsuya Kimura Yoshiyuki M Source Type: research

Can Warfarin be replaced by non-vitamin K anticoagulants in prosthetic valves?
In this report, the authors discussed the published data related to NOACs use in prosthetic valves highlighting the proposed mechanisms of NOACs failure and other controversial data regarding their efficacy and safety in prosthetic valves.EXPERT OPINION: Although NOACs have proven to be even safer and more effective alternatives to vitamin K antagonists (VKAs) in several indications for anticoagulation, the data regarding their safety and efficacy in prosthetic heart valves is still debatable. The controversial data regarding NOACs use in prosthetic valves renders it difficult to define specific guideline-recommendation fo...
Source: Expert Review of Cardiovascular Therapy - November 24, 2022 Category: Cardiology Authors: Mahmoud Abdelnabi Juthipong Benjanuwattra Ashraf Ahmed Abdallah Almaghraby Source Type: research

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients
Conclusion: Eight functional PK-related genetic variants were not significantly associated with bleeding from either rivaroxaban or apixaban in more than 2,000 AF self-identified white outpatients.
Source: Frontiers in Pharmacology - November 24, 2022 Category: Drugs & Pharmacology Source Type: research

Self-reported adherence to direct oral anticoagulants versus warfarin therapy in a specialized thrombosis service —a cross-sectional study of patients in a Canadian Health Region
ConclusionsSelf-reported medication adherence was similar between warfarin and DOACs. Since suboptimal adherence is associated with poor clinical outcomes and increased costs, various stakeholders should emphasize the importance of medication adherence to oral anticoagulants at each patient encounter.
Source: European Journal of Clinical Pharmacology - November 18, 2022 Category: Drugs & Pharmacology Source Type: research

Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19
CONCLUSION AND RELEVANCE: Approximately 52% of patients on warfarin were eligible for DOACs. This presents an opportunity to reduce patient exposure to health care settings and health care utilization in the setting of COVID-19. Increased costs of DOACs need to be assessed.PMID:36373362 | PMC:PMC9663271 | DOI:10.1177/10600280221136874
Source: The Annals of Pharmacotherapy - November 14, 2022 Category: Drugs & Pharmacology Authors: Rachel Hess Elizabeth Renner Erin Mouland Denise Sutter-Long Nghi Ha Source Type: research

Incidence of stroke, systemic embolism and bleeding events in patients without anticoagulation based on real-world data in Japan: a retrospective cohort study
Conclusions Approximately one-third of the patients do not receive any anticoagulation in the modern DOAC era in Japan. The SSE rate increases by the CHADS2 score. The SSE rate is low in patients with a CHADS2 score <1, supporting no indication of anticoagulation in current guidelines. In patients with a CHADS2 score >1, the use of anticoagulant drug therapy is recommended because of a higher risk of stroke.
Source: BMJ Open - November 10, 2022 Category: General Medicine Authors: Tanizawa, K., Nishimura, Y., Sera, S., Yaguchi, D., Okada, A., Nishikawa, M., Tamaru, S., Nagai, N. Tags: Open access, Epidemiology Source Type: research

Comparison of primary and secondary stroke prevention in patients with nonvalvular atrial fibrillation: Results from the RAFFINE registry
Atrial fibrillation (AF) is a predictor of severe stroke and early death in acute ischemic stroke patients.1 The prevalence of AF has increased as the Japanese population has aged.2 AF has been more common among patients with ischemic stroke than previously reported.3 In particular, AF patients with a history of stroke or TIA have had higher risks for stroke, hemorrhagic events, and death compared to those without.4,5 In these previous studies, most patients received warfarin for anticoagulation therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - November 7, 2022 Category: Neurology Authors: Kazuo Yamashiro, Ryota Tanaka, Sakiko Miyazaki, Katsumi Miyauchi, Hidemori Hayashi, Yuji Nishizaki, Shuko Nojiri, Satoru Suwa, Masataka Sumiyosi, Yuji Nakazato, Takao Urabe, Nobutaka Hattori, Tohru Minamino, Hiroyuki Daida Source Type: research

Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial
CONCLUSIONS: There was inadequate power to draw any conclusion regarding rates of major or clinically relevant non-major bleeding comparing apixaban and warfarin in patients with AF and ESKD on hemodialysis. Clinically relevant bleeding events were approximately 10-fold more frequent than stroke or systemic embolism among this population on anticoagulation, highlighting the need for future randomized studies evaluating the risks versus benefits of anticoagulation among patients with AF and ESKD on hemodialysis.PMID:36335914 | DOI:10.1161/CIRCULATIONAHA.121.054990
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Sean D Pokorney Glenn M Chertow Hussein R Al-Khalidi Dianne Gallup Pat Dignaco Kurt Mussina Nisha Bansal Crystal A Gadegbeku David A Garcia Samira Garonzik Renato D Lopes Kenneth W Mahaffey Kelly Matsuda John P Middleton Jennifer A Rymer George H Sands Ra Source Type: research